Compared to the findings of the phase III study of the first long-acting G-CSF, pegfilgrastim in breast cancer patients receiving TA chemotherapy, the mean DSN in the first cycle was similar (1.3 days versus 1.8 days) [15]. Here, CSF3 is linked to breast cancer.